BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 3, 2026
Home » Newsletters » BioWorld

BioWorld

June 10, 2020

View Archived Issues
Cancer-cell-antibody-attack

Genmab banks $750M up front in $3.9B oncology alliance with Abbvie

DUBLIN – Shares in Genmab A/S gained 5% during trading on Nasdaq June 10 on news of an oncology alliance with Abbvie Inc., in which it is banking $750 million up front and up to $3.15 billion in development, regulatory and commercial milestones for up to seven next-generation antibody-based therapeutics. Read More
Gloved hand holding COVID-19 vaccine vial, syringe

BIO Digital: COVID-19 vaccines outlook offers reasons for hope, concern

Threads of hope and caution stitched together a wide-ranging appraisal of COVID-19 vaccines at June 9's BIO Digital plenary, "A Way Forward." The good news, delivered by one of the world's most sober participants in the pandemic response, mercifully came first. Read More
Brain scan illustration

Public-private partnerships key to development of new Alzheimer’s disease therapies

According to Todd Haim, chief of the Office of Small Business Research at the National Institute on Aging (NIA), Alzheimer’s disease (AD) is a major issue. In his opening remarks on a BIO Digital panel, titled “Brave Innovations: public and private solutions to advance Alzheimer’s therapeutics and diagnostics in a risk-averse climate,” he provided data showing why new treatments for AD and AD-related dementias (ADRD) are desperately needed. Read More
business-data-dollar.png

Checkmate lands $85M series C to continue TLR9 wars

Checkmate Pharmaceuticals Inc., of Cambridge, Mass., completed an $85 million series C to continue developing CMP-001, a differentiated Toll-like receptor 9 (TLR9) agonist, for treating anti-PD-1-refractory melanoma and to study additional indications that include front-line melanoma and head and neck squamous cell carcinoma. Read More
eye-analysis.png

Opthea’s OPT-302 meets primary endpoints in phase IIa diabetic macular edema trial

PERTH, Australia – Melbourne, Australia-based Opthea Ltd. announced positive top-line results of its phase IIa trial evaluating safety and efficacy of OPT-302 administered with Eylea (aflibercept, Regeneron Pharmaceuticals Inc.) in treatment-refractory patients with persistent diabetic macula edema (DME). Read More

Canbridge moves to expand rare disease pipeline with UMass collaboration

BEIJING – Rare disease specialist Canbridge Pharmaceuticals Inc., of Beijing, said it is collaborating with the Horae Gene Therapy Center at the University of Massachusetts (UMass) Medical School to conduct gene therapy research with a focus on neuromuscular conditions. The move is expected to add new assets to the company’s portfolio. Read More
Capitol.png

Senator: Now’s the time to plan for next pandemic

Before the lessons of COVID-19 fade into yesterday’s news, Congress should start preparing for the next pandemic, Sen. Lamar Alexander (R-Tenn.) is advising. As the chair of the Senate Health, Education, Labor and Pensions Committee, the senator issued a white paper Tuesday identifying areas that must be addressed. Read More

India posts draft rules for compassionate use of unapproved drugs

HONG KONG – India’s Ministry of Health and Family Welfare (MOHFW) has drafted rules for the manufacturing, import and the compassionate use of unapproved drugs in the treatment of patients. Read More

Astellas reports positive results for roxadustat phase III study

HONG KONG – Astellas Pharma Inc. reported positive results from phase III of its DOLOMITES study comparing the efficacy and safety of roxadustat to that of darbepoetin alfa in treating anemia in nondialysis-dependent, stage 3 to 5 chronic kidney disease (CKD) patients. Read More

Appointments and advancements for June 10, 2020

New hires and promotions in the biopharma industry, including: Azafaros, Confo, Gritstone, Legend, Oric, Tonix, Verrica. Read More

Financings for June 10, 2020

Biopharmas raising money in public or private financings, including: Aileron, Amyris, Antibe, Appili, Applied Molecular Transport, Can-Fite, Fulcrum, Immunic, Innocan, Legend, Oncology Venture, Vedanta. Read More

In the clinic for June 10, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Biondvax, Catalyst, Dermata, Devonian, Impel, Merck, Opthea, Orpheris, Pfizer, Pulmatrix, Tychan. Read More

Other news to note for June 10, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Adgero, Alligator, Alphamab, Aptevo, Autotelic, Biocryst, Bryn, Bryologyx, Curadigm, Debiopharm, Delmar, Denali, Dyadic, E-therapeutics, Intomics, Izana, J&J, L.E.A.F., Lyvgen, Mateon, Melinta, Menarini, Merck, Metuchen, Midatech, Mitsubishi Tanabe, Nanobiotix, Nantkwest, Neurotrope, Orgenesis, Ose, Panacea, Pharmabcine, Qualigen, Refana, Secura, Stemline, Supernus, Takeda, Tetraphase, US Worldmeds, Zealand. Read More

Regulatory actions for June 10, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bacainn, Curis, F2G, Fulcrum, Pharnext, Redhill, Rezolute, Vertex. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

    BioWorld Science
    Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • Anthony Fauci at Senate hearing 7-29

    Fauci’s silence may put him in contempt of Congress

    BioWorld
    After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
  • Mitochondria

    Seed funding at Adjuvia to treat mitochondrial dysfunction

    BioWorld Science
    Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing